Ocular Therapeutix (OCUL) News Today $8.73 -0.22 (-2.46%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.72 -0.01 (-0.06%) As of 06/13/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Courier Capital LLC Boosts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Courier Capital LLC increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 173.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 154,266 shares of the biopharmJune 10, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 48.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2June 8, 2025 | marketbeat.comAmeriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Ameriprise Financial Inc. lifted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 82.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 89,772 shares of the biopharmaceutical company's stock after pJune 3, 2025 | marketbeat.comTwo Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Two Sigma Investments LP boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 252,939 shares of theJune 2, 2025 | marketbeat.comNuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Nuveen Asset Management LLC trimmed its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 17.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 414,104 shares of the biopharmaceutical coJune 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for OCUL Q1 Earnings?Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Ocular Therapeutix in a research report issued on Thursday, May 29th. HC Wainwright analyst Y. Chen expects that the biopharmaceutical company will post earningsJune 2, 2025 | marketbeat.comH.C. Wainwright maintains $15 target on Ocular Therapeutix stockMay 31, 2025 | investing.comVoloridge Investment Management LLC Has $286,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Voloridge Investment Management LLC lowered its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 71.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,483 shares of the biopharmaceutical coMay 31, 2025 | marketbeat.comMillennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Millennium Management LLC acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 447,237 shares of the biopharmaceutical company's stock, valued atMay 31, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DEBank of America Corp DE trimmed its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 43.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 437,071 shares of the biopharmaceutical compMay 31, 2025 | marketbeat.comOcular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Thursday.May 30, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,862 SharesOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Sanjay Nayak sold 1,862 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $7.17, for a total value of $13,350.54. Following the completion of the sale, the insider now owns 281,623 shares of the company's stock, valued at $2,019,236.91. This trade represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.May 29, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Peter Kaiser Sells 2,974 SharesOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Peter Kaiser sold 2,974 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.17, for a total transaction of $21,323.58. Following the completion of the transaction, the insider now owns 207,104 shares in the company, valued at $1,484,935.68. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 29, 2025 | marketbeat.comInsider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 3,024 Shares of StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Jeffrey S. Heier sold 3,024 shares of the stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $21,712.32. Following the transaction, the insider now owns 262,974 shares in the company, valued at approximately $1,888,153.32. This trade represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.May 29, 2025 | marketbeat.comPravin Dugel Sells 21,219 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Pravin Dugel sold 21,219 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the sale, the insider now directly owns 3,499,099 shares in the company, valued at $25,123,530.82. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.May 29, 2025 | marketbeat.comDemystifying Ocular Therapeutix: Insights From 7 Analyst ReviewsMay 29, 2025 | benzinga.comOcular Therapeutix (NASDAQ:OCUL) Shares Down 4.8% - Here's What HappenedOcular Therapeutix (NASDAQ:OCUL) Shares Down 4.8% - What's Next?May 29, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Trading Up 5.4% - Still a Buy?Ocular Therapeutix (NASDAQ:OCUL) Trading 5.4% Higher - Should You Buy?May 29, 2025 | marketbeat.comOcular Therapeutix chief scientific officer sells $21,712 in stockMay 29, 2025 | investing.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. decreased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 20.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 394,400 shares of the biopharmaceutical company's stock afMay 28, 2025 | marketbeat.comInsider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 1,862 Shares of StockMay 28, 2025 | insidertrades.comBNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)BNP Paribas Financial Markets increased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 110.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 75,400 shares of the biopharmaceutical compaMay 26, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from BrokeragesOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to thMay 23, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AGDeutsche Bank AG lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 45.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 456,120 shares of the biopharmaceutical company's sMay 22, 2025 | marketbeat.comOcular Therapeutix at RBC Conference: Strategic Advancements in Wet AMD TrialsMay 21, 2025 | uk.investing.comGraham Capital Management L.P. Takes $321,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Graham Capital Management L.P. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 37,577 shares of the biopharmaceutical company's stMay 20, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Second Line Capital LLCSecond Line Capital LLC boosted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 29.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 340,098 shares of the bioMay 19, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 43.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,935,924 shares of the biopharmaceuticalMay 19, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust CorpNorthern Trust Corp boosted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 5.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,314,871 shares of the biopharmaceutical company's stock afMay 19, 2025 | marketbeat.comPolar Asset Management Partners Inc. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Polar Asset Management Partners Inc. cut its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 20.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 394,400 shares of the biopharmaceutical companyMay 18, 2025 | marketbeat.comBalyasny Asset Management L.P. Acquires New Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Balyasny Asset Management L.P. acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 97,553 shares of the biopharmaceutical company's stock, valuedMay 17, 2025 | marketbeat.comPatient Square Capital LP Raises Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Patient Square Capital LP lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 100.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 470,919 shares of the biopharmaMay 16, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 22.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 270,422 shares of the biopharmaceutical company's sMay 15, 2025 | marketbeat.comRichard L. Md Lindstrom Purchases 10,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) Director Richard L. Md Lindstrom purchased 10,000 shares of the company's stock in a transaction on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.May 14, 2025 | marketbeat.comOcular Therapeutix™ to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard L. Md Lindstrom Acquires 10,000 SharesMay 13, 2025 | insidertrades.comHC Wainwright Expects Weaker Earnings for Ocular TherapeutixOcular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for Ocular Therapeutix in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceMay 10, 2025 | marketbeat.comWilliam Blair Cuts Earnings Estimates for Ocular TherapeutixOcular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Investment analysts at William Blair lowered their Q2 2025 EPS estimates for shares of Ocular Therapeutix in a research note issued on Monday, May 5th. William Blair analyst L. Hanbury-Brown now expects that the biopharmaceutical company willMay 10, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for OCUL FY2026 Earnings?Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Ocular Therapeutix in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst Y. Chen expects that the biopharmaceuMay 9, 2025 | marketbeat.comDeep Track Capital LP Grows Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Deep Track Capital LP increased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 0.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,836,282 shares of the biopharmaceutical company's stock afterMay 9, 2025 | marketbeat.comAnalyst Expectations For Ocular Therapeutix's FutureMay 8, 2025 | nasdaq.comOcular Therapeutix (NASDAQ:OCUL) Trading Down 6.5% on Analyst DowngradeOcular Therapeutix (NASDAQ:OCUL) Shares Down 6.5% Following Analyst DowngradeMay 8, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 by Analysts at Needham & Company LLCNeedham & Company LLC reduced their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday.May 8, 2025 | marketbeat.com212,944 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by First Trust Advisors LPFirst Trust Advisors LP bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 212,944 shares of the biopharmaceutical company's stock, vMay 8, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down - What's Next?Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down - Time to Sell?May 7, 2025 | marketbeat.comAnalysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS NumbersMay 7, 2025 | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Announces Quarterly Earnings ResultsOcular Therapeutix (NASDAQ:OCUL - Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.09). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.May 7, 2025 | marketbeat.comAptus Capital Advisors LLC Has $2.90 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Aptus Capital Advisors LLC raised its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 29.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 339,750 shares of the biopharmaceutical company's stock after acquiring an additional 7May 7, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $5.46 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Price T Rowe Associates Inc. MD cut its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 34.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 638,964 shares of the biopharmaceutical company's sMay 7, 2025 | marketbeat.comOcular Therapeutix First Quarter 2025 Earnings: Misses ExpectationsMay 6, 2025 | finance.yahoo.com Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Media Mentions By Week OCUL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼1.360.88▲Average Medical News Sentiment OCUL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼35▲OCUL Articles Average Week Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TLX News Today NUVL News Today AXSM News Today ADMA News Today PCVX News Today AKRO News Today RYTM News Today ZLAB News Today PTCT News Today CYTK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCUL Stock Free OCUL Stock Alerts